EpiCast Report: Chronic Obstructive Pulmonary Disease - Epidemiology Forecasts to 2025

EpiCast Report: Chronic Obstructive Pulmonary Disease - Epidemiology Forecasts to 2025

  • July 2017 •
  • 37 pages •
  • Report ID: 3524427 •
  • Format: PDF
EpiCast Report: Chronic Obstructive Pulmonary Disease - Epidemiology Forecasts to 2025

Summary
Chronic obstructive pulmonary disease (COPD), also known as chronic obstructive lung disease (COLD), is a condition characterized by difficulty in breathing, shortness of breath, wheezing, chest tightness, and other respiratory symptoms that progress over time. The disease is often caused by smoking; however, long-term exposure to other lung irritants, such as pollution, smoke from vehicle emissions and power stations, chemical fumes, and dust, can also lead to the development of COPD (NHLBI, 2013).

In the 8MM, epidemiologists forecast that the total prevalent cases of COPD will increase from 65,991,432 cases in 2015 to 76,066,482 cases in 2025 at an Annual Growth Rate (AGR) of 1.53%. The US will have the highest number of total prevalent cases of COPD among the 8MM throughout the forecast period with 33,028,213 cases in 2015 and 39,284,075 cases in 2025.The US had the highest number of diagnosed prevalent cases of COPD in the 8MM in both 2015 and 2025, at 13,791,975 cases in 2015, and 16,033,432 cases in 2025.

The report "EpiCast Report: Chronic Obstructive Pulmonary Disease - Epidemiology Forecasts to 2025" provides an overview of the risk factors, comorbidities, and the global and historical trends for COPD in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and Australia). It includes a 10-year epidemiological forecast for the total prevalent cases of COPD (diagnosed and undiagnosed cases) and the diagnosed prevalent cases of COPD, which are segmented by sex and age (35-44, 45-54, 55-64, 65-74, and 75 years and older).

Scope
- The Chronic obstructive pulmonary disease (COPD) EpiCast Report provides an overview of the risk factors and global trends of COPD in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and Australia). It includes a 10-year epidemiological forecast for the total prevalent cases of COPD (diagnosed and undiagnosed cases) and the diagnosed prevalent cases of COPD, which are segmented by sex and age (35-44, 45-54, 55-64, 65-74, and 75 years and older). The diagnosed prevalent cases of COPD are further segmented by the new GOLD 2011 severity stage (GOLD A, GOLD B, GOLD C, and GOLD D) using the COPD Assessment Test (CAT) scores and the modified Medical Research Council (mMRC) dyspnea scores.
- The COPD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to buy
The COPD EpiCast report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global COPD market.
- Quantify patient populations in the global COPD market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for COPD therapeutics in each of the markets covered.
- Understand severity stages of COPD cases by CAT score and mMRC scores.
Loading...

We are very sorry, but an error occurred.
Please contact support@reportbuyer.com if the problem remains.